Cargando…

Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal‐bolus insulin therapy: An open‐label, single‐center, parallel, randomized control study

The efficacy of the administration of sodium‐glucose co‐transporter 2 inhibitor or the co‐administration of sodium‐glucose co‐transporter 2 inhibitor and dipeptidyl peptidase‐4 inhibitor to insulin therapy is not well known. A total of 58 patients with type 2 diabetes, admitted for glycemic control,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okajima, Fumitaka, Nagamine, Tomoko, Nakamura, Yuko, Hattori, Naomi, Sugihara, Hitoshi, Emoto, Naoya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415488/ https://www.ncbi.nlm.nih.gov/pubmed/27762088 http://dx.doi.org/10.1111/jdi.12588

Ejemplares similares

Basal–Bolus Insulin Therapy with Gla-300 During Hospitalization Reduces Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study
por: Okajima, Fumitaka, et al.
Publicado: (2018)

Effect of Glycemic Control on Chylomicron Metabolism and Correlation between Postprandial Metabolism of Plasma Glucose and Chylomicron in Patients with Type 2 Diabetes Treated with Basal-bolus Insulin Therapy with or without Vildagliptin
por: Okajima, Fumitaka, et al.
Publicado: (2017)

Painless destructive thyroiditis in a patient with resistance to thyroid hormone: a case report
por: Nagamine, Tomoko, et al.
Publicado: (2019)

Behavioral economics survey of patients with type 1 and type 2 diabetes
por: Emoto, Naoya, et al.
Publicado: (2015)

A socioeconomic and behavioral survey of patients with difficult-to-control type 2 diabetes mellitus reveals an association between diabetic retinopathy and educational attainment
por: Emoto, Naoya, et al.
Publicado: (2016)

New-onset graves’ disease after the initiation of nivolumab therapy for gastric cancer: a case report
por: Yamada, Hiroshi, et al.
Publicado: (2020)

Risk Preferences, Rationality of Choices, and Willingness to Pay for Preventive Medicine in Patients with Graves’ Thyrotoxicosis
por: Emoto, Naoya, et al.
Publicado: (2021)

Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report
por: Okada, Shuichi, et al.
Publicado: (2014)

Can Fasting Glucose Levels or Post-Breakfast Glucose Fluctuations Predict the Occurrence of Nocturnal Asymptomatic Hypoglycemia in Type 1 Diabetic Patients Receiving Basal-Bolus Insulin Therapy with Long-Acting Insulin?
por: Mitsuishi, Sumie, et al.
Publicado: (2015)

Duration of Nocturnal Hypoglycemia Before Seizures
por: Buckingham, Bruce, et al.
Publicado: (2008)

Fasting plasma glucose level-based formula for estimating starting daily dose in basal-bolus insulin therapy
por: Nagao, Mototsugu, et al.
Publicado: (2023)

Terbutaline and the Prevention of Nocturnal Hypoglycemia in Type 1 Diabetes
por: Cooperberg, Benjamin A., et al.
Publicado: (2008)

Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open‐label study (SOAR‐KOBE Study)
por: Miura, Hiroshi, et al.
Publicado: (2019)

The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen
por: Castellano, Elena, et al.
Publicado: (2018)

Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study
por: Ueno, Hiroaki, et al.
Publicado: (2018)

Correction to: The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen
por: Castellano, Elena, et al.
Publicado: (2018)

Abnormal nocturnal behavior due to hypoglycemia: A case report
por: Weng, Ning, et al.
Publicado: (2019)

Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model
por: Morishita, Asahiro, et al.
Publicado: (2022)

Bolus Calculator Reduces Hypoglycemia in the Short Term and Fear of Hypoglycemia in the Long Term in Subjects with Type 1 Diabetes (CBMDI Study)
por: Vallejo Mora, María del Rosario, et al.
Publicado: (2017)

Insulin Pump Therapy With Automated Insulin Suspension in Response to Hypoglycemia: Reduction in nocturnal hypoglycemia in those at greatest risk
por: Choudhary, Pratik, et al.
Publicado: (2011)

Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study
por: Ito, Daisuke, et al.
Publicado: (2017)

Short Report: Treatment Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal–Bolus Type 1): 2-year results of a randomized clinical trial
por: Bode, B W, et al.
Publicado: (2013)

Initial Basal and Bolus Rates and Basal Rate Variability During Pump Treatment in Children and Adolescents
por: Demir, Günay, et al.
Publicado: (2021)

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
por: Takahashi, Hirokazu, et al.
Publicado: (2021)

Ipragliflozin/tozinameran: Diabetic ketoacidosis: 2 case reports
Publicado: (2022)

Defective Awakening Response to Nocturnal Hypoglycemia in Patients with Type 1 Diabetes Mellitus
por: Schultes, Bernd, et al.
Publicado: (2007)

Prevention of Nocturnal Hypoglycemia Using Predictive Alarm Algorithms and Insulin Pump Suspension
por: Buckingham, Bruce, et al.
Publicado: (2010)

Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules
por: Hosokawa, Kohshiro, et al.
Publicado: (2019)

Association of diabetic ketoacidosis, severe hypoglycemia and glycemic control among children and young adults with type 1 diabetes mellitus treated with premixed versus basal-bolus insulin therapy
por: Chou, Wei-Yu, et al.
Publicado: (2018)

Accuracy of Bolus and Basal Rate Delivery of Different Insulin Pump Systems
por: Freckmann, Guido, et al.
Publicado: (2019)

Efficacy of bolus insulin calculation by a mobile-based bolus advisor: An open label clinical trial
por: Siavash, Mansour, et al.
Publicado: (2015)

Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096)
por: Ratner, R, et al.
Publicado: (2011)

Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice
por: Kamezaki, Michitsugu, et al.
Publicado: (2018)

A concise and practical stereoselective synthesis of ipragliflozin L-proline
por: Ma, Shuai, et al.
Publicado: (2017)

Reply to: “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
por: van Kleef, Laurens A., et al.
Publicado: (2022)

Autonomic Cardiac Regulation During Spontaneous Nocturnal Hypoglycemia in Patients With Type 1 Diabetes
por: Koivikko, Minna L., et al.
Publicado: (2012)

Machine Learning Models for Nocturnal Hypoglycemia Prediction in Hospitalized Patients with Type 1 Diabetes
por: Berikov, Vladimir B., et al.
Publicado: (2022)

Autonomic cardiac regulation during spontaneous nocturnal hypoglycemia in children with type 1 diabetes
por: Bachmann, Sara, et al.
Publicado: (2021)

The role of sulfonylurea plus basal insulin on glycemic variability compared to basal bolus regime in T2D patients
por: Freire, Paula Vieira, et al.
Publicado: (2015)

Making Sense of BGM and CGM Data for a Basal-Bolus Insulin User
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b6bp35i3177cbr8srinbt7j94s